BSX
FY2026 Q1 · Calendar Q2 2026
Boston Scientific Corporation
Boston Scientific delivered Q1 FY2026 results that beat on both lines: 9.4% organic revenue growth and adjusted EPS of $0.80 versus $0.79 consensus. However, the stock's trajectory has been defined by the guidance reduction that accompanied those results. Management lowered full-year organic growth to 6.5%-8% and adjusted EPS to $3.34-$3.41, citing unexpected headwinds in electrophysiology, WATCHMAN, and urology. Shares initially rose approximately 9% on the earnings day but subsequently drifted about 13% lower, trading at $45.38 as of July 29, 2026, a 40% discount to the $75.45 analyst consensus target. The dislocation reflects unresolved concerns about the sustainability of EP growth amid intensifying PFA competition from Medtronic, J&J, and Abbott, WATCHMAN volume softness, urology underperformance, and integration risk from the pending Penumbra acquisition. Core growth drivers…
EPS surprise+1.5%
Market move+9.0%
